{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:03:36Z","timestamp":1792789416191,"version":"4.5.0"},"reference-count":281,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-02636"],"award-info":[{"award-number":["2021-02636"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2021-02636"],"award-info":[{"award-number":["2021-02636"]}],"id":[{"id":"https:\/\/ror.org\/03zttf063","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Swedish Cancer Society","award":["23 2975"],"award-info":[{"award-number":["23 2975"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swedish Cancer Society","award":["25 4774"],"award-info":[{"award-number":["25 4774"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"crossref"}]},{"award":["23 2975"],"award-info":[{"award-number":["23 2975"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"publisher"}]},{"award":["25 4774"],"award-info":[{"award-number":["25 4774"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Swedish government and the county councils","award":["ALFGBG-1005656"],"award-info":[{"award-number":["ALFGBG-1005656"]}]},{"name":"King Gustav V Jubilee Clinic Cancer Research Foundation","id":[{"id":"https:\/\/ror.org\/052nngb38","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sahlgrenska University Hospital Research Funds","id":[{"id":"https:\/\/ror.org\/04vgqjj36","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Assar Gabrielsson Cancer Research Foundation","id":[{"id":"https:\/\/ror.org\/052nngb38","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Herbert & Karin Jacobsson Foundation"},{"name":"Royal Society of Arts and Sciences Fund in Gothenburg","id":[{"id":"https:\/\/ror.org\/03zsxwj64","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are the most common subtype of NETs, and their incidence continues to increase worldwide. Many NETs express somatostatin receptors (SSTRs), enabling molecular imaging and treatment with radiolabeled somatostatin analogs (SSTAs). [177Lu]Lu-DOTATATE is an established treatment for advanced SSTR-positive NETs, but complete and durable responses remain uncommon. This review summarizes current clinical experience with [177Lu]Lu-DOTATATE and emerging SSTR-targeting radiopharmaceuticals and examines strategies to improve PRRT efficacy. Treatment may be enhanced at several interconnected steps, including increasing receptor availability and tumor targeting, improving radiopharmaceutical uptake and absorbed dose, preventing repair of radiation-induced damage, suppressing cellular stress adaptation and survival, and promoting tumor cell elimination. These approaches include radiation priming and fractionation, somatostatin analog pretreatment, epigenetic modifiers, inhibitors of DNA repair and cellular survival pathways, immunotherapy, and chemotherapy-based combinations. PARP, DNA-PK, and HSP90 inhibitors and chemotherapy-based combinations have shown particularly strong preclinical or clinical evidence, whereas mTOR inhibitors, tyrosine kinase inhibitors, Hedgehog inhibitors, immunotherapy, NAMPT inhibitors, p53 stabilization, and epigenetic modifiers remain under investigation. Ongoing development of novel radiopharmaceuticals, personalized dosimetry, retreatment strategies, and rational combinations is expected to refine PRRT and improve outcomes for patients with NETs.<\/jats:p>","DOI":"10.3390\/ijms27198709","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:09:25Z","timestamp":1790683765000},"page":"8709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Somatostatin Receptor-Targeting Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors: Biological Rationale, Combination Strategies, and Clinical Perspectives"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3568-8091","authenticated-orcid":false,"given":"Hana","family":"Bakr","sequence":"first","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden"},{"name":"Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden"},{"name":"Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, SE-413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3199-2634","authenticated-orcid":false,"given":"Amin","family":"Al-Awar","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden"},{"name":"Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-9786","authenticated-orcid":false,"given":"Johan K. E.","family":"Spetz","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden"},{"name":"Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-4368","authenticated-orcid":false,"given":"Eva B.","family":"Forssell-Aronsson","sequence":"additional","affiliation":[{"name":"Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden"},{"name":"Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, SE-405 30 Gothenburg, Sweden"},{"name":"Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Region V\u00e4stra G\u00f6taland, SE-413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Takayanagi, D., Cho, H., Machida, E., Kawamura, A., Takashima, A., Wada, S., Tsunoda, T., Kohno, T., and Shiraishi, K. (2022). Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 14.","DOI":"10.3390\/cancers14051119"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Maqsood, M.H., Tameez Ud Din, A., and Khan, A.H. (2019). Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. Cureus, 11.","DOI":"10.7759\/cureus.3986"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-019-04499-x","article-title":"Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"47","author":"Adant","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s13139-017-0505-6","article-title":"Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors","volume":"52","author":"Kim","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13139-018-0517-x","article-title":"Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives","volume":"52","author":"Hirmas","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yordanova, A., and Ahmadzadehfar, H. (2021). Combination Therapies with PRRT. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101005"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors","volume":"50","author":"Basu","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2015.10.005","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"30","author":"Brabander","year":"2016","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.110.075101","article-title":"Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention","volume":"51","author":"Vegt","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Strosberg, J.R., Caplin, M.E., Kunz, P.L., Ruszniewski, P.B., Bodei, L., Hendifar, A.E., Mittra, E., Wolin, E.M., Yao, J.C., and Pavel, M.E. (2021). Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J. Clin. Oncol., 39.","DOI":"10.1200\/JCO.2021.39.15_suppl.4112"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","article-title":"The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: A systematic review and meta-analysis","volume":"146","author":"Zhang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1530\/ERC-19-0186","article-title":"The next generation of peptide receptor radionuclide therapy","volume":"26","author":"Brabander","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-026-01379-z","article-title":"Management of Peptide Receptor Radionuclide Therapy Toxicities in Neuroendocrine Neoplasm Patients","volume":"27","author":"Mohindroo","year":"2026","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: First clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7150\/thno.13702","article-title":"[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study","volume":"6","author":"Baum","year":"2016","journal-title":"Theranostics"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Halfdanarson, T.R., Reidy, D.L., Vijayvergia, N., Daniel, M., Halperin, G.G., Kong, G., Michael, M., Leyden, S., Grozinsky-Glasberg, S., and Sorbye, H. (2022, January 20\u201322). Pivotal phase III COMPOSE trial will compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors. Proceedings of the 2022 ASCO Gastrointestinal Cancers Symposium, San Fransisco, CA, USA.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS514"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/wjnm.wjnm_160_20","article-title":"Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review","volume":"20","author":"Koh","year":"2021","journal-title":"World J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-019-04530-1","article-title":"Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors","volume":"47","author":"Liu","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7150\/thno.23491","article-title":"Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy","volume":"8","author":"Tian","year":"2018","journal-title":"Theranostics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2967\/jnumed.118.209841","article-title":"Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors","volume":"59","author":"Zhang","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Alsadik, S., Gnanasegaran, G., Chen, L., Quigley, A.M., Mandair, D., Toumpanakis, C., Caplin, M., and Navalkissoor, S. (2022). Single centre retrospective review of outcome of (177) Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors. J. Neuroendocrinol., 34.","DOI":"10.1111\/jne.13210"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2967\/jnumed.124.268880","article-title":"Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!","volume":"66","author":"Deshayes","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40336-025-00685-0","article-title":"The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: Literature and practical aspects","volume":"13","author":"Dia","year":"2025","journal-title":"Clin. Transl. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1159\/000542328","article-title":"Lu-PRRT Used More Intensively on Advanced Gastro-Entero-Pancreatic and Lung Neuroendocrine Neoplasms: Preliminary Results on Toxicity from a Randomized Study","volume":"115","author":"Grassi","year":"2025","journal-title":"Neuroendocrinology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kuiper, J., Zoetelief, E., Brabander, T., de Herder, W.W., and Hofland, J. (2025). Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. J. Neuroendocrinol., 37.","DOI":"10.1111\/jne.13469"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s00259-024-06725-7","article-title":"Lutetium [(177)Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: Rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study","volume":"51","author":"Lastoria","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1007\/s00259-025-07750-w","article-title":"Peptide receptor radionuclide therapy in neuroendocrine tumours: Advances, combination strategies, and future directions","volume":"53","author":"Virgolini","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40336-018-0267-x","article-title":"Peptide receptor radionuclide therapy for neuroendocrine tumours","volume":"6","author":"Yusuf","year":"2018","journal-title":"Clin. Transl. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000336086","article-title":"Radionuclide therapy via SSTR: Future aspects from experimental animal studies","volume":"97","author":"Spetz","year":"2013","journal-title":"Neuroendocrinology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gomes-Porras, M., C\u00e1rdenas-Salas, J., and \u00c1lvarez-Escol\u00e1, C. (2020). Somatostatin Analogs in Clinical Practice: A Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051682"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Romiani, A., Spetz, J., Shubbar, E., Lind, D.E., Hallberg, B., Palmer, R.H., and Forssell-Aronsson, E. (2021). Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08551-8"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tranon.2017.12.003","article-title":"Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor","volume":"11","author":"Montelius","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/therapeutics1010003","article-title":"Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model","volume":"1","author":"Romiani","year":"2024","journal-title":"Therapeutics"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Romiani, A., Simonsson, K., Pettersson, D., Al-Awar, A., Rassol, N., Bakr, H., Lind, D.E., Umapathy, G., Spetz, J., and Palmer, R.H. (2024). Comparison of (177)Lu-octreotate and (177)Lu-octreotide for treatment in human neuroblastoma-bearing mice. Heliyon, 10.","DOI":"10.1016\/j.heliyon.2024.e31409"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: Initial results from the P-PRRT trial","volume":"46","author":"Buteau","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.113.125336","article-title":"Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"55","author":"Ezziddin","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): Feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Lundin","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate in Patients with Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years\u2019 Assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: Prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00259-014-2735-5","article-title":"177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: Results from a phase II study","volume":"41","author":"Paganelli","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-015-3041-6","article-title":"Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine","volume":"42","author":"Sabet","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00268-009-0387-6","article-title":"[177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: The value of measuring absorbed dose to the kidney","volume":"34","author":"Bernhardt","year":"2010","journal-title":"World J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants","volume":"111","author":"Welin","year":"2021","journal-title":"Neuroendocrinology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2967\/jnumed.120.260760","article-title":"Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study","volume":"63","author":"Zidan","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0032-1311603","article-title":"Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma\u2013tools for choice of radionuclide therapy","volume":"44","author":"Spetz","year":"2012","journal-title":"Horm. Metab. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.124.268617","article-title":"(177)Lu-DOTATATE Plus Capecitabine Versus (177)Lu-DOTATATE Alone in Patients with Advanced Grade 1\/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Puranik, A.D., Dev, I.D., Yadav, S., Rangarajan, V., Agrawal, A., Basu, S., Chaudhari, V.A., Ramaswamy, A., Ostwal, V., and Bhandare, M.S. (2025). PReCedeNT trial: Phase III randomized-controlled trial of Lutetium\u2014177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15111-x"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00259-025-07606-3","article-title":"Peptide receptor radionuclide therapy alone or in combination with temozolomide plus\/minus capecitabine in [(18)F]FDG-positive metastatic neuroendocrine tumors","volume":"53","author":"Santo","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chan, D.L., Sjoquist, K.M., Ransom, D.T., Wyld, D., Wilson, K., Gebski, V., Murray, J., Kiberu, A.D., Burge, M.E., and Macdonald, W. (2026). [(177)Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial. Eur. J. Cancer, 241.","DOI":"10.1016\/j.ejca.2026.116781"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/1078-0432.CCR-25-1884","article-title":"A multicenter phase II randomized controlled trial comparing 177Lu-Dotatate\/capecitabine combination treatment with 177Lu-Dotatate monotherapy in patients with neuroendocrine tumors","volume":"32","author":"Becx","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s12149-026-02169-1","article-title":"Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: Extension of the Japanese phase I and phase I\/II study","volume":"40","author":"Kobayashi","year":"2026","journal-title":"Ann. Nucl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1021\/acs.molpharmaceut.6c00126","article-title":"Pharmacokinetics and Dosimetry of (177)Lu-DOTATATE in Patients with Advanced Well-Differentiated, Gastroenteropancreatic Neuroendocrine Tumors: Results from a Substudy of the Phase 3 XT-XTR008-3-01 Trial","volume":"23","author":"Ma","year":"2026","journal-title":"Mol. Pharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1097\/RLU.0000000000006578","article-title":"Targeted Alpha Therapy with [225Ac]Ac-DOTATATE Versus Salvage Retreatment PRRT with [177Lu]Lu-DOTATATE in Progressive Metastatic Neuroendocrine Tumor Patients After Initial Course of [177Lu]Lu-DOTATATE Treatment: An Observational Study Comparing the Therapeutic Response, Survival, and Clinical Toxicity","volume":"51","author":"Agrawal","year":"2026","journal-title":"Clin. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(26)00108-7","article-title":"[(177)Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): A randomised, controlled, phase 2 trial","volume":"27","author":"Baudin","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(26)00604-5","article-title":"[(177)Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): A phase 3, multicentre, randomised, open-label, superiority trial","volume":"408","author":"Walter","year":"2026","journal-title":"Lancet"},{"key":"ref_72","unstructured":"ITM Isotope Technologies Munich SE (2026, September 22). ITM Announces FDA Acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide (ITM-11) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). Available online: https:\/\/www.itm-radiopharma.com\/news\/press-releases\/press-releases-detail\/itm-announces-fda-acceptance-of-new-drug-application-nda-and-pdufa-date-for-n-c-a-177lu-edotreotide-itm-11-in-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-747\/."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.120.248658","article-title":"Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE","volume":"62","author":"Liu","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.apsb.2024.05.022","article-title":"Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study","volume":"15","author":"Guo","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/RLU.0000000000006162","article-title":"Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor: Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability","volume":"50","author":"Wang","year":"2025","journal-title":"Clin. Nucl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.124.269389","article-title":"Multicycle Dosimetric Behavior and Dose-Effect Relationships in [(177)Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy","volume":"66","author":"Kayal","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2967\/jnumed.125.270573","article-title":"Dosimetry Results from the Phase 1b\/3 ACTION-1 Trial of [(225)Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs","volume":"67","author":"Sgouros","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bodei, L., Gnanasegaran, G., Giammarile, F., Pavel, M., Ambrosini, V., Baum, R.P., H\u00f6rsch, D., Howe, J.R., Cremonesi, M., and El-Haddad, G. (2026). Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours. EANM J., 3.","DOI":"10.1016\/j.eanmj.2026.100017"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Chauhan, A., Weiss, H.L., Kunos, C., Jayswal, R., Konda, B., Soares, H.P., Li, D., Halfdanarson, T.R., Mulcahy, M.F., and Jacene, H.A. (2026). Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388). Clin. Cancer Res., OF1\u2013OF10.","DOI":"10.1158\/1078-0432.CCR-26-0686"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2967\/jnumed.125.270654","article-title":"Targeted beta(-)-Particle Plus Conversion and Auger-Electron Therapy with (161)Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study","volume":"67","author":"Fricke","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Vermeulen, K., Van de Voorde, M., Segers, C., Coolkens, A., Rodriguez Perez, S., Daems, N., Duchemin, C., Crabbe, M., Opsomer, T., and Saldarriaga Vargas, C. (2022). Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [(153)Sm]Sm-DOTA-TATE. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122566"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1007\/s00259-025-07351-7","article-title":"Novel framework for response evaluation criteria in grade 1\/2 neuroendocrine tumors (RECIN) following [(177)Lu]Lu-DOTATATE therapy: Post-hoc analysis of the phase 2 LuCAP trial","volume":"52","author":"Satapathy","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.1016\/S1470-2045(26)00145-2","article-title":"Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): A modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)","volume":"27","author":"Deroose","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s41181-025-00395-y","article-title":"Drug interactions involving therapeutic radiopharmaceuticals: A systematic review","volume":"11","author":"Gacon","year":"2026","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sung, M.J., and Park, N. (2026). Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies. J. Clin. Med., 15.","DOI":"10.3390\/jcm15051713"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41419-025-08205-8","article-title":"Platelet aging and desialylation increase apoptotic priming and BCL-X(L) dependence","volume":"17","author":"Grozovsky","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.nucmedbio.2014.07.010","article-title":"Time- and dose rate-related effects of internal (177)Lu exposure on gene expression in mouse kidney tissue","volume":"41","author":"Schuler","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: The value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Spetz, J.K.E., Florido, M.H.C., Fraser, C.S., Qin, X., Choiniere, J., Yu, S.J., Singh, R., Friesen, M., Rubin, L.L., and Salem, J.E. (2022). Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities. Sci. Adv., 8.","DOI":"10.1126\/sciadv.abn6579"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/jnci\/djae163","article-title":"Older adults with cancer and common comorbidities-challenges and opportunities in improving their cancer treatment outcomes","volume":"116","author":"Chen","year":"2024","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_92","first-page":"437","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Langen, B., Vorontsov, E., Spetz, J., Swanpalmer, J., Sihlbom, C., Helou, K., and Forssell-Aronsson, E. (2022). Age and sex effects across the blood proteome after ionizing radiation exposure can bias biomarker screening and risk assessment. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-10271-3"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.clon.2019.01.002","article-title":"Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Dose-Volume Response Relationships for Paediatric Cancer Patients","volume":"31","author":"Constine","year":"2019","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Keller, K.M., Koetsier, J., Schild, L., Amo-Addae, V., Eising, S., van den Handel, K., Ober, K., Koopmans, B., Essing, A., and van den Boogaard, M.L. (2023). The potential of PARP as a therapeutic target across pediatric solid malignancies. BMC Cancer, 23.","DOI":"10.1186\/s12885-022-10319-7"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00066-023-02132-3","article-title":"Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients","volume":"200","author":"Paal","year":"2024","journal-title":"Strahlenther. Onkol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Pearson, A.D.J., Federico, S., Gatz, S.A., Ortiz, M., Lesa, G., Scobie, N., Gounaris, I., Weiner, S.L., Weigel, B., and Unger, T.J. (2023). Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur. J. Cancer, 190.","DOI":"10.1016\/j.ejca.2023.112950"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ccell.2016.11.011","article-title":"Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics","volume":"31","author":"Sarosiek","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/0008-5472.CAN-22-1337","article-title":"Radiotherapy-Induced Neurocognitive Impairment Is Driven by Heightened Apoptotic Priming in Early Life and Prevented by Blocking BAX","volume":"83","author":"Singh","year":"2023","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhao, S.J., Prior, D., Heske, C.M., and Vasquez, J.C. (2024). Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy. Cancers, 16.","DOI":"10.3390\/cancers16091648"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2967\/jnumed.125.270202","article-title":"[(177)Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors","volume":"67","author":"Sood","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/ERC-17-0445","article-title":"The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines","volume":"25","author":"Hofving","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41588-019-0509-5","article-title":"Reply to \u2018H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines\u2019","volume":"51","author":"Alvarez","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2967\/jnumed.124.268902","article-title":"(177)Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial","volume":"66","author":"Hallqvist","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_105","first-page":"261","article-title":"NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study","volume":"30","author":"Claringbold","year":"2015","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_106","first-page":"164","article-title":"Efficacy of Everolimus Combined with (177)Lu-Dotatate in the Treatment of Neuroendocrine Tumors","volume":"39","author":"Aljubran","year":"2024","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kim, C., Liu, S.V., Subramaniam, D.S., Torres, T., Loda, M., Esposito, G., and Giaccone, G. (2020). Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000980"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Aicher, A., Sindrilaru, A., Crisan, D., Thaiss, W., Steinacker, J., Beer, M., Wiegel, T., Scharffetter-Kochanek, K., Beer, A.J., and Prasad, V. (2022). Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071466"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2967\/jnumed.121.262344","article-title":"Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00259-007-0688-7","article-title":"Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours","volume":"35","author":"Krenning","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-010-1483-4","article-title":"177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide","volume":"37","author":"Hubble","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","article-title":"Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours","volume":"38","author":"Claringbold","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_113","first-page":"561","article-title":"Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors","volume":"27","author":"Claringbold","year":"2012","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00259-014-2788-5","article-title":"Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)","volume":"41","author":"Kong","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-014-2906-4","article-title":"Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours","volume":"42","author":"Kashyap","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000434723","article-title":"Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy","volume":"103","author":"Claringbold","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","article-title":"Peptide Receptor Radionuclide Therapy Combined with Chemotherapy in Patients with Neuroendocrine Tumors","volume":"44","author":"Yordanova","year":"2019","journal-title":"Clin. Nucl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Cullinane, C., Waldeck, K., Kirby, L., Rogers, B.E., Eu, P., Tothill, R.W., and Hicks, R.J. (2020). Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-67199-9"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.7150\/thno.84628","article-title":"A genome-wide CRISPR\/Cas9 screen identifies DNA-PK as a sensitiser to (177)Lutetium-DOTA-octreotate radionuclide therapy","volume":"13","author":"Waldeck","year":"2023","journal-title":"Theranostics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.7150\/thno.82963","article-title":"DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo","volume":"13","author":"Reuvers","year":"2023","journal-title":"Theranostics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1530\/ERC-18-0509","article-title":"177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition","volume":"26","author":"Hofving","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-019-04673-1","article-title":"The radiosensitizer Onalespib increases complete remission in (177)Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts","volume":"47","author":"Lundsten","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/0008-5472.CAN-11-2089","article-title":"mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer","volume":"73","author":"Pool","year":"2013","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-014-0021-y","article-title":"Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: Further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model","volume":"4","author":"Bison","year":"2014","journal-title":"EJNMMI Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Zellmer, J., Yen, H.Y., Kaiser, L., Gildehaus, F.J., Boning, G., Steiger, K., Hacker, M., Bartenstein, P., Todica, A., and Haug, A.R. (2022). Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123102"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Sandblom, V., Spetz, J.K.E., Shubbar, E., Montelius, M., Stahl, I., Swanpalmer, J., Nilsson, O., and Forssell-Aronsson, E. (2020). Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233720"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Spetz, J.K.E., Langen, B., Rudqvist, N., Parris, T.Z., Helou, K., Nilsson, O., and Forssell-Aronsson, E. (2017). Hedgehog inhibitor sonidegib potentiates (177)Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3524-x"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2967\/jnumed.116.177584","article-title":"NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors","volume":"58","author":"Elf","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sandblom, V., Spetz, J.K.E., Shubbar, E., Montelius, M., Stahl, I., Swanpalmer, J., Nilsson, O., and Forssell-Aronsson, E. (2019). Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225260"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00259-023-06462-3","article-title":"p53 stabilisation potentiates [(177)Lu]Lu-DOTATATE treatment in neuroblastoma xenografts","volume":"51","author":"Berglund","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"24693","DOI":"10.18632\/oncotarget.25266","article-title":"Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor","volume":"9","author":"Purohit","year":"2018","journal-title":"Oncotarget"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","article-title":"Combining [(177)Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer","volume":"51","author":"Rauch","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_135","first-page":"1287","article-title":"The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells","volume":"55","author":"Lundsten","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13550-025-01346-z","article-title":"Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses","volume":"15","author":"Engbers","year":"2025","journal-title":"EJNMMI Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","article-title":"The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells","volume":"85","author":"Zitzmann","year":"2007","journal-title":"Neuroendocrinology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13550-024-01135-0","article-title":"Enhancing [(177)Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics","volume":"14","author":"Cheng","year":"2024","journal-title":"EJNMMI Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Lundsten, S., Berglund, H., Jha, P., Krona, C., Hariri, M., Nelander, S., Lane, D.P., and Nestor, M. (2021). p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids. Biomolecules, 11.","DOI":"10.3390\/biom11111695"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2967\/jnumed.118.224048","article-title":"Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro","volume":"60","author":"Jin","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kotzerke, J., Buesser, D., Naumann, A., Runge, R., Huebinger, L., Kliewer, A., Freudenberg, R., and Brogsitter, C. (2022). Epigenetic-Like Stimulation of Receptor Expression in SSTR2 Transfected HEK293 Cells as a New Therapeutic Strategy. Cancers, 14.","DOI":"10.3390\/cancers14102513"},{"key":"ref_142","first-page":"G963","article-title":"Pancreatic tumoral cell line AR42J: An amphicrine model","volume":"266","author":"Christophe","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1073\/pnas.48.7.1184","article-title":"Hormone-producing cultures of adrenal and pituitary tumor origin","volume":"48","author":"Buonassisi","year":"1962","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0016-5085(91)90004-5","article-title":"Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth","volume":"101","author":"Evers","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_145","first-page":"5810","article-title":"Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse","volume":"46","author":"Kyriazis","year":"1986","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(79)80080-4","article-title":"Transplantation of azaserine-induced carcinomas of pancreas in rats","volume":"7","author":"Longnecker","year":"1979","journal-title":"Cancer Lett."},{"key":"ref_147","first-page":"281","article-title":"In vitro growth of a cell line originated from a human insulinoma","volume":"6","author":"Gueli","year":"1987","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9440(10)64017-5","article-title":"A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake","volume":"158","author":"Bernhardt","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1677\/ERC-06-0033","article-title":"A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis","volume":"14","author":"Johanson","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_150","first-page":"174","article-title":"Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2","volume":"27","author":"Dalmo","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_151","first-page":"3502","article-title":"Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties","volume":"40","author":"Gazdar","year":"1980","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1016\/0006-2952(87)90308-X","article-title":"Inhibition of N-diethylnitrosamine metabolism by human lung cancer cell lines with features of well differentiated pulmonary endocrine cells","volume":"36","author":"Hegedus","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_153","first-page":"1951","article-title":"Establishment and characterization of three novel cell lines\u2014P-STS, L-STS, H-STS\u2014Derived from a human metastatic midgut carcinoid","volume":"29","author":"Pfragner","year":"2009","journal-title":"Anticancer. Res."},{"key":"ref_154","first-page":"513","article-title":"Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I)","volume":"8","author":"Pfragner","year":"1996","journal-title":"Int. J. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0165-4608(94)00185-E","article-title":"Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines","volume":"80","author":"Cooley","year":"1995","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_156","first-page":"596","article-title":"Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma","volume":"71","author":"Kaku","year":"1980","journal-title":"Gan"},{"key":"ref_157","unstructured":"Leong, S.S., Horoszewicz, J.S., Shimaoka, K., Friedman, M., Kawinski, E., Song, M.J., Ziegel, Z., Chu, T.M., Baylin, S.B., and Mirand, E.A. (1981). A new cell line for study of human medullary carcinoma. Advances in Thyroid Neoplasia, Field Educational Italia."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/endo-113-5-1587","article-title":"Mouse pituitary tumor line secreting only the alpha-subunit of the glycoprotein hormones: Development from a thyrotropic tumor","volume":"113","author":"Ridgway","year":"1983","journal-title":"Endocrinology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Salomonsson, S.L., Engbers, P.A.M., Nonnekens, J., and Bondza, S. (2026). SSTR2 receptor states and cellular metabolism modulate 177Lu-DOTATATE binding affinity. EANM Innov., 4.","DOI":"10.1016\/j.eanmi.2026.100288"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.nucmedbio.2006.07.010","article-title":"Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro","volume":"33","author":"Oddstig","year":"2006","journal-title":"Nucl. Med. Biol."},{"key":"ref_162","first-page":"759","article-title":"Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses","volume":"26","author":"Oddstig","year":"2011","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_163","first-page":"644","article-title":"Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice","volume":"22","author":"Bernhardt","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s00259-005-1877-x","article-title":"111In-labelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy","volume":"32","author":"Capello","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_165","first-page":"324","article-title":"Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy","volume":"51","author":"Melis","year":"2007","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_166","first-page":"3652","article-title":"Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment","volume":"59","author":"Froidevaux","year":"1999","journal-title":"Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.nucmedbio.2009.09.006","article-title":"Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: Animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model","volume":"37","author":"Hanin","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0969-8051(97)00122-4","article-title":"Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats","volume":"24","author":"Breeman","year":"1997","journal-title":"Nucl. Med. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","article-title":"Influence of lanreotide on uptake of (68)Ga-DOTATATE in patients with neuroendocrine tumours: A prospective intra-patient evaluation","volume":"46","author":"Aalbersberg","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2967\/jnumed.119.226332","article-title":"A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors","volume":"60","author":"Galne","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1007\/s00259-025-07648-7","article-title":"Normal organ [(68)Ga]DOTATOC uptake during PRRT: Challenging the assumption of stable background shaped by cold somatostatin analogues treatment","volume":"53","author":"Baltzinger","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s12020-011-9524-8","article-title":"Cross-talk and modulation of signaling between somatostatin and growth factor receptors","volume":"40","author":"Kumar","year":"2011","journal-title":"Endocrine"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/endo.138.2.4951","article-title":"Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor","volume":"138","author":"James","year":"1997","journal-title":"Endocrinology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0026-895X(25)08674-2","article-title":"Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells","volume":"46","author":"Vidal","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Rivera, J.A., Alturaihi, H., and Kumar, U. (2005). Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J. Carcinog., 4.","DOI":"10.1186\/1477-3163-4-10"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: Seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"R315","DOI":"10.1530\/ERC-17-0012","article-title":"Genetic and epigenetic drivers of neuroendocrine tumours (NET)","volume":"24","author":"Wiedmer","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1210\/en.2007-1525","article-title":"Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications","volume":"149","author":"Torrisani","year":"2008","journal-title":"Endocrinology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2018","journal-title":"Oncotarget"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2022.09.009","article-title":"Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy","volume":"176","author":"Evans","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Guenter, R.E., Aweda, T., Carmona Matos, D.M., Whitt, J., Chang, A.W., Cheng, E.Y., Liu, X.M., Chen, H., Lapi, S.E., and Jaskula-Sztul, R. (2019). Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors. Cancers, 11.","DOI":"10.3390\/cancers11060767"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.surg.2019.05.092","article-title":"Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment","volume":"167","author":"Guenter","year":"2020","journal-title":"Surgery"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1159\/000545073","article-title":"Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells with Combined Inhibition of Class I HDACs and LSD1","volume":"115","author":"Auernhammer","year":"2025","journal-title":"Neuroendocrinology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1159\/000441849","article-title":"Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells","volume":"103","author":"Arvidsson","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Klomp, M.J., Hofland, L.J., van den Brink, L., van Koetsveld, P.M., Dogan, F., de Ridder, C.M.A., Stuurman, D.C., Clahsen-van Groningen, M.C., de Jong, M., and Dalm, S.U. (2022). The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14010173"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Klomp, M.J., van den Brink, L., van Koetsveld, P.M., de Ridder, C.M.A., Stuurman, D.C., Lowik, C., Hofland, L.J., and Dalm, S.U. (2023). Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: From cells to mice. Life Sci., 334.","DOI":"10.1016\/j.lfs.2023.122173"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/1535-7163.MCT-22-0798","article-title":"Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model","volume":"22","author":"Sharma","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Murphy, R., Chander, G., Martinez, M., Ward, C., Khan, S.R., Naik, M., Barwick, T., Aboagye, E., and Sharma, R. (2023). Study protocol of LANTana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK. BMJ Open, 13.","DOI":"10.1136\/bmjopen-2023-075221"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CCO.0000000000001158","article-title":"Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?","volume":"37","author":"Meyers","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Shah, R.G., Merlin, M.A., Adant, S., Zine-Eddine, F., Beauregard, J.M., and Shah, G.M. (2021). Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. Cancers, 13.","DOI":"10.3390\/cancers13020232"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.nucmedbio.2008.05.003","article-title":"Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation","volume":"35","author":"Nayak","year":"2008","journal-title":"Nucl. Med. Biol."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Pivonello, R., Munster, P.N., Terzolo, M., Ferrigno, R., Simeoli, C., Puglisi, S., Bali, U., and Moraitis, A.G. (2021). Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.793262"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/EC-20-0089","article-title":"The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome","volume":"9","author":"Ceccato","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm (2020)"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/srao.2003.50002","article-title":"The mechanism of action of radiosensitization of conventional chemotherapeutic agents","volume":"13","author":"Lawrence","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-016-0247-y","article-title":"Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1","volume":"7","author":"Dalmo","year":"2017","journal-title":"EJNMMI Res."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Elvborn, M., Shubbar, E., and Forssell-Aronsson, E. (2022). Hyperfractionated Treatment with (177)Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model. Cancers, 14.","DOI":"10.3390\/cancers14010235"},{"key":"ref_198","first-page":"1542","article-title":"Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model","volume":"45","author":"Schmitt","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2967\/jnumed.120.243543","article-title":"Peptide Receptor Radionuclide Therapy with (67)Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model","volume":"61","author":"Cullinane","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_200","unstructured":"Andersson, P., Forssell-Aronsson, E., Gr\u00e9tarsd\u00f3ttir, J., Johanson, V., W\u00e4ngberg, B., Nilsson, O., Fj\u00e4lling, M., and Ahlman, H. (1996, January 7\u201310). Biokinetics and dosimetry after repeated injections of 111In-DTPA-D-Phe1-octreotide. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, USA. ORISE 99-0164."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2967\/jnumed.125.271039","article-title":"Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to (177)Lu-DOTATATE in Neuroendocrine Tumors","volume":"67","author":"Macsuka","year":"2026","journal-title":"J. Nucl. Med."},{"key":"ref_202","unstructured":"Warfvinge, C.F., Kapidzic, S.C., Gustafsson, J., Jessen, L., Svensson, J., Sundlov, A., and Sjogreen Gleisner, K. (2026). Patient Survival and Its Relation to Tumor Absorbed Dose in [(177)Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors. J. Nucl. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2967\/jnumed.125.269470","article-title":"Establishing In Vitro Dosimetric Models and Dose-Effect Relationships for (177)Lu-DOTATATE in Neuroendocrine Tumors","volume":"66","author":"Tamborino","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Pouget, J.P., Lozza, C., Deshayes, E., Boudousq, V., and Navarro-Teulon, I. (2015). Introduction to radiobiology of targeted radionuclide therapy. Front. Med., 2.","DOI":"10.3389\/fmed.2015.00012"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2018.01.006","article-title":"Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after (177)Lu[Lu]-octreotate therapy","volume":"60","author":"Spetz","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1038\/sj.onc.1210868","article-title":"DNA double-strand breaks: Their cellular and clinical impact?","volume":"26","author":"Jeggo","year":"2007","journal-title":"Oncogene"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Reuvers, T.G.A., Heredia-Genestar, J.M., Garrido-Hernandez, G., Brandt, R.M.C., Tamborino, G., and Nonnekens, J. (2026). Preclinical comparison of radiobiological and radiosensitizing effects in peptide receptor radionuclide therapy and external beam radiotherapy. EANM Innov., 3.","DOI":"10.1016\/j.eanmi.2026.100274"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","article-title":"The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art","volume":"84","author":"Schreiber","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: Recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Nile, D.L., Rae, C., Hyndman, I.J., Gaze, M.N., and Mairs, R.J. (2016). An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2656-8"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Mohiuddin, I.S., and Kang, M.H. (2019). DNA-PK as an Emerging Therapeutic Target in Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00635"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA Repair in Cancer: Beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Obata, H., Ogawa, M., and Zalutsky, M.R. (2023). DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071926"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Maier, P., Hartmann, L., Wenz, F., and Herskind, C. (2016). Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010102"},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Spetz, J.K.E., Montelius, M.E., Berger, E., Johansson, J.A.M., Rassol, N., Ljungberg, M., and Forssell-Aronsson, E.B. (2026). Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]LuDOTATATE therapy. BMC Cancer, in press.","DOI":"10.21203\/rs.3.rs-9833935\/v1"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s11030-025-11314-3","article-title":"Recent progress in the development of HSP90 inhibitors: Structure-activity relationship and biological evaluation studies","volume":"30","author":"Kumar","year":"2026","journal-title":"Mol. Divers."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1007\/s11030-025-11160-3","article-title":"Recent progress and structural insights of potential Hsp90 inhibitors as anticancer agents","volume":"29","author":"Singh","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1038\/s41598-020-62293-4","article-title":"The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: An in vitro and in vivo approach","volume":"10","author":"Spiegelberg","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/BST20110609","article-title":"Cross-talk between mitogenic Ras\/MAPK and survival PI3K\/Akt pathways: A fine balance","volume":"40","author":"Aksamitiene","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2004.03.005","article-title":"Role of cell cycle in mediating sensitivity to radiotherapy","volume":"59","author":"Pawlik","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00129039-200206000-00008","article-title":"Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: Progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms","volume":"10","author":"Wang","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/1871520611009030250","article-title":"New medical strategies for midgut carcinoids","volume":"10","author":"Nilsson","year":"2010","journal-title":"Anticancer. Agents Med. Chem."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Nassim, R., Mansure, J.J., Chevalier, S., Cury, F., and Kassouf, W. (2013). Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: A novel strategy for treatment. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065257"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Das, S., and Dasari, A. (2021). Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther. Adv. Med. Oncol., 13.","DOI":"10.1177\/17588359211018047"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Xu, J., Shen, L., Li, J., Zhou, Z., Bai, C., Li, Z., Chi, Y., Li, E., Yu, X., and Xu, N. (2025). Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p). Eur. J. Cancer, 222.","DOI":"10.1016\/j.ejca.2025.115398"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in Patients with Advanced Grade 1\/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: Status 2023","volume":"14","author":"Santo","year":"2024","journal-title":"Theranostics"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejca.2022.12.031","article-title":"Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours\u2014A systematic review and meta-analysis","volume":"182","author":"Das","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1677\/ERC-07-0108","article-title":"Snail and Sonic Hedgehog activation in neuroendocrine tumors of the ileum","volume":"14","author":"Fendrich","year":"2007","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2012.0474","article-title":"Hedgehog signaling in human medullary thyroid carcinoma: A novel signaling pathway","volume":"23","author":"Bohinc","year":"2013","journal-title":"Thyroid."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/SLA.0b013e318236bc0f","article-title":"Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms","volume":"254","author":"Fendrich","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhang, Y., Li, K., and Xue, S. (2023). Hedgehog signaling and the glioma-associated oncogene in cancer radioresistance. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1257173"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1158\/0008-5472.CAN-14-1346","article-title":"Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers","volume":"74","author":"Gan","year":"2014","journal-title":"Cancer Res."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2016.04.014","article-title":"A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer","volume":"99","author":"Pietanza","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Ghanem, M.S., Caffa, I., Monacelli, F., and Nencioni, A. (2024). Inhibitors of NAD(+) Production in Cancer Treatment: State of the Art and Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042092"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-019-0500-2","article-title":"Transcriptional effects of (177)Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice","volume":"9","author":"Spetz","year":"2019","journal-title":"EJNMMI Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1080\/09553002.2025.2542318","article-title":"Late apoptotic effects after treatment with (177)Lu-octreotate in small-intestine neuroendocrine GOT1 tumor model","volume":"101","author":"Elvborn","year":"2025","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/MPA.0000000000001794","article-title":"Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience","volume":"50","author":"Gile","year":"2021","journal-title":"Pancreas"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Jimenez, C., Subbiah, V., Stephen, B., Ma, J., Milton, D., Xu, M., Zarifa, A., Akhmedzhanov, F.O., Tsimberidou, A., and Habra, M.A. (2020). Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers, 12.","DOI":"10.3390\/cancers12082307"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: Clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/bs.ircmb.2018.07.004","article-title":"T Cells and Regulated Cell Death: Kill or Be Killed","volume":"342","author":"Spetz","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11154-021-09647-z","article-title":"Present and future of immunotherapy in Neuroendocrine Tumors","volume":"22","author":"Albertelli","year":"2021","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"767","DOI":"10.7150\/thno.79806","article-title":"Radiopharmaceuticals heat anti-tumor immunity","volume":"13","author":"Sun","year":"2023","journal-title":"Theranostics"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2967\/jnumed.123.265391","article-title":"Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors","volume":"64","author":"Esfahani","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: Prognostic factors, incidence and course","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2967\/jnumed.123.266843","article-title":"SPECT\/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [(177)Lu]Lu-DOTATATE","volume":"65","author":"Blakkisrud","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000362558","article-title":"Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up","volume":"99","author":"Kesavan","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/ERC-21-0082","article-title":"Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET","volume":"28","author":"Kesavan","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic Therapies for Cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","article-title":"Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II","volume":"24","author":"Sun","year":"2016","journal-title":"J. Drug Target."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/cbin.10215","article-title":"Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro","volume":"38","author":"Bryan","year":"2014","journal-title":"Cell Biol. Int."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11936-018-0627-x","article-title":"Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment","volume":"20","author":"Spetz","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-15-0978","article-title":"XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer","volume":"22","author":"Torres","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1\u2014From biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrm3115","article-title":"Mitotic catastrophe: A mechanism for avoiding genomic instability","volume":"12","author":"Vitale","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molcel.2015.11.006","article-title":"Targeting Mitosis in Cancer: Emerging Strategies","volume":"60","author":"Thu","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1158\/1078-0432.CCR-12-3458","article-title":"Molecular pathogenesis of neuroendocrine tumors: Implications for current and future therapeutic approaches","volume":"19","author":"Oberg","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2014.05.002","article-title":"Targeting apoptosis for anticancer therapy","volume":"31","author":"Fulda","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcdb.2014.12.005","article-title":"Smac mimetics as IAP antagonists","volume":"39","author":"Fulda","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/cdd.2017.183","article-title":"Why do BCL-2 inhibitors work and where should we use them in the clinic?","volume":"25","author":"Montero","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Daniels, V.W., Zoeller, J.J., van Gastel, N., McQueeney, K.E., Parvin, S., Potter, D.S., Fell, G.G., Ferreira, V.G., Yilma, B., and Gupta, R. (2021). Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Sci. Signal, 14.","DOI":"10.1126\/scisignal.abc7405"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/ERC-12-0338","article-title":"Neuroendocrine tumours: Cracking the epigenetic code","volume":"20","author":"Karpathakis","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/onc.2014.379","article-title":"Epigenetic changes in gastroenteropancreatic neuroendocrine tumours","volume":"34","author":"Mapelli","year":"2015","journal-title":"Oncogene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:16:34Z","timestamp":1790684194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/19\/8709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":281,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["ijms27198709"],"URL":"https:\/\/doi.org\/10.3390\/ijms27198709","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}